Ypsilon Therapeutics
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Oncology
Ypsilon Therapeutics is expanding the reach of antibody therapeutics. Ypsilon is advancing a new class of cancer therapies with TCR mimics (TCRm), designed to address unmet needs in solid tumors. TCRm are novel antibodies that bind peptide/MHC complexes, unlocking access to tumor-specific intracellular targets beyond the reach of conventional antibodies. Ypsilon’s TCRm T cell engagers bispecific antibodies bring the precision of T cell receptor recognition with the potency and good manufacturability of antibody therapeutics. TCRm driving immune responses by redirecting a patient’s own immune system to eliminate their tumors. The company’s lead program targets antigens highly expressed in cancers such as triple-negative breast cancer with limited expression in normal tissues. Ypsilon is led by two seasoned immunologist and drug hunters, Dr. Dongxing Zha and Dr. Michael Kalos. Backed by a CPRIT Seed Award and strong scientific expertise, Ypsilon is driving transformative therapies toward clinical development for patients with limited treatment options.
Company HQ City:
Houston
Company HQ State:
TX
Company HQ Country:
United States
Year Founded:
2022
CEO
Dongxing Zha, Ph.D.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}